Protagen develops new approaches for personalized medicine and is a specialist in the development of new companion diagnostics (CDx) for autoimmune diseases and immunoncology based on autoantibodies. Protagen’s technology is based on blood analysis of patients with chronic diseases. This involves the search for autoantibodies with a higher concentration in autoimmune patients, among others. The proprietary SeroTag process allows the systematic identification and validation of novel biomarkers in patient blood samples for personalized medicine.
MIG invests in Protagen 2006
Exit to Oncimmune 2019